abstract: BACKGROUND: Although several studies have shown a positive association between evidence of anti-adenovirus 36 (Ad-36) antibodies (Ad-36 exposure) and (1) @entity28 and (2) serum @entity165 in animals, there is limited research demonstrating this association in @entity1 . There is also limited research on transmission, presentation and demographics of @entity9504 . DESIGN: (1) Body mass (body mass index (BMI)), (2) fasting serum @entity165 and @entity412 levels and (3) demographic characteristics were compared between Ad-36 seropositive and seronegative groups. The majority of subjects were matched as cases versus controls on a number of demographic variables. SUBJECTS: A total of 150 @entity28 and 150 lean active-duty military personnel were studied. MEASUREMENTS: Subjects completed a questionnaire regarding demographic and behavioral characteristics. Subject serum samples were tested by serum neutralization assay for the presence of anti-Ad-36 antibodies. RESULTS: In all, 34% of @entity28 and 39% of lean subjects had Ad-36 exposure, an insignificant difference. Serum @entity165 and @entity412 levels were significantly higher among the @entity28 subjects than among the lean, but there were no associations between serum @entity165 and @entity412 levels and Ad-36 exposure. Positive associations were found between Ad-36 exposure and age, race and gender. CONCLUSION: The study stands in contrast to previous work that has shown a positive relationship between Ad-36 exposure and (1) @entity28 , and (2) levels of serum @entity165 and @entity1674 . In this study there was no association in either case. Unanticipated relationships between Ad-36 exposure and age, race and gender were found, and this is the first time that such a link between Ad-36 exposure and demographics has been found.

title: Adenovirus 36 seropositivity is strongly associated with race and gender, but not XXXX , among US military personnel.

entities_list: @entity28 :: ('MESH:D009765', 'Disease') :: ['obese', 'obesity']

entities_list: @entity1674 :: ('MESH:D014280', 'Chemical') :: ['triglycerides']

entities_list: @entity412 :: ('CHEBI:17855', 'Chemical') :: ['triglyceride']

entities_list: @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']

answer: @entity28 :: (MESH:D009765,Disease) :: ['obesity']


abstract: BACKGROUND: @entity28 affects more than half a billion @entity1 worldwide, including one-third of @entity1 and @entity1 in the United States. @entity28 is associated with higher postoperative complication rates after @entity572 ( @entity572 ). It remains unknown whether @entity28 @entity1 progress to revision @entity572 faster than nonobese @entity1 . METHODS: A total of 257 consecutive primary THAs referred to an academic tertiary care center for revision @entity572 were retrospectively stratified according to preoperative body mass index (BMI), reason for revision @entity572 , and time from primary to revision @entity572 . RESULTS: When examining primary THAs referred for revision @entity572 , increasing BMI adversely affected the mean time to revision @entity572 . The percentage of primary THAs revised at 5 years was 25% for a BMI of 18-25, 38% for a BMI of 25-30, 56% for a BMI of 30-35, 73% for a BMI of 35-40, and 75% for a BMI of greater than 40 (P < .001). The percentage of primary THAs revised at 15 years was 70%, 82%, 87%, 94%, and 100%, respectively (P < .001). A significant increase in early revision @entity572 for @entity1349 / @entity3061 in @entity28 @entity1 (56%, 23/41) when compared with the nonobese @entity1 (12%, 10/83, P < .001, relative risk ratio  = 4.7). CONCLUSION: Preoperative BMI influences the time of failure of primary THAs referred to an academic tertiary care for revision @entity572 as well as the mechanism of failure. Specifically, @entity28 increased in the relative risk of early revision @entity572 due to @entity1349 / @entity3061 by 4.7 fold.

title: XXXX is Associated With Early Total Hip Revision for @entity1349 .

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'people', 'men']

entities_list: @entity28 :: ('MESH:D009765', 'Disease') :: ['Obesity', 'obese', 'obesity']

entities_list: @entity3061 :: ('MESH:D010014', 'Disease') :: ['osteolysis']

entities_list: @entity572 :: ('MESH:D006617', 'Disease') :: ['THA', 'total hip arthroplasty']

entities_list: @entity1349 :: ('MESH:D011475', 'Disease') :: ['aseptic loosening']

answer: @entity28 :: (MESH:D009765,Disease) :: ['Obesity']


abstract: OBJECTIVE: To review history, biology, and medical aspects associated with fish and shellfish @entity4968 . DATA SOURCES: Current literature, various Web sites, and Halstead's Volume II of Poisonous and Venomous Marine Animals. STUDY SELECTION: Determined by author. DATA SELECTION: Determined by author. DATA SYNTHESIS: Fish and shellfish @entity4968 occur through the natural event of the food chain. Fish and shellfish consume algae that contain toxin-producing dinoflagellates. As a result they become contaminated and the toxin is concentrated as it moves up the food chain. Fish and shellfish can tolerate high levels of toxins, thereby appearing healthy while posing a significant danger to @entity1 . The toxin cannot be detected by sight, smell, or taste and is not destroyed by cooking or freezing. Thus @entity1 becomes an unsuspecting victim. There are several types of @entity4968 that occur through fish and shellfish consumption. They are ciguatera and @entity9963 ; and @entity8442 , diarrheic, @entity2359 , and @entity20301 . A different toxin produces each of these poisonings; however, sources and symptoms may be similar among these poisonings making them difficult to diagnose. These intoxications can vary in severity from mild to fatal depending on the type and amount of toxin ingested. Age and underlying illnesses may also contribute to the outcome of these poisonings. CONCLUSION: Though @entity1 are aware of health warnings and may think they are important, it is @entity1 nature to think that "this could not possibly happen to me". Therefore, they fail to make the necessary changes required to reduce the incidence of fish and shellfish @entity4968 .

title: Fish and shellfish XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'man', 'people']

entities_list: @entity20301 :: ('MESH:D057096', 'Disease') :: ['amnesic shellfish poisoning']

entities_list: @entity9963 :: ('MESH:D005393', 'Disease') :: ['scombroid fish poisoning']

entities_list: @entity8442 :: ('MESH:D007418', 'Disease') :: ['paralytic']

entities_list: @entity4968 :: ('MESH:D011041', 'Disease') :: ['poisoning']

entities_list: @entity2359 :: ('MESH:D020258', 'Disease') :: ['neurotoxic']

answer: @entity4968 :: (MESH:D011041,Disease) :: ['poisoning']


abstract: OBJECTIVES: The objectives of this study were to examine the trends in the prevalence of @entity164 2 @entity6 @entity1 with comorbid @entity101 and blood pressure (BP) control rates in the United States and determine factors associated with these outcomes. METHODS: We used data from National Health and Nutrition Examination Surveys (NHANES) III (1988-1994) and NHANES 1999-2004, a cross-sectional sample of the noninstitutionalized US populations. Type 2 @entity6 @entity1 were identified as @entity1 at least 30 years of age with physician-diagnosed @entity6 who were taking insulin or oral antidiabetic drugs to manage the condition. A diagnosis of @entity101 was based on physician diagnosis, treatment with antihypertensive medications, or BP at least 140/90 mmHg. BP control was defined as @entity6 @entity1 who maintained BP <130/80 mmHg. Logistic regression was used to estimate risks of high BP, and odds of high BP treatment and control rates, after adjusting for demographic and clinical risk factors. RESULTS: The age-adjusted prevalence of @entity6 @entity1 and those with @entity101 increased significantly from 5.8 to 7.1% and 3.9 to 4.7%, respectively, from NHANES III to NHANES 1999-2004. Among @entity6 @entity1 with @entity101 , @entity1 who were treated with medication or lifestyle or behavioral modification therapy have increased significantly from 76.5 to 87.8% during the observation period. The proportion of @entity1 who controlled BP increased from 15.9 to 29.6%, but 70% of @entity1 still did not meet the target BP goal. CONCLUSION: Aggressive public health efforts are needed to improve BP control in @entity164 2 @entity6 @entity1 with @entity101 .

title: Trends in blood pressure control and treatment among XXXX 2 @entity6 with comorbid @entity101 in the United States: 1988-2004.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetic', 'diabetes']

answer: @entity164 :: (MESH:D017827,Disease) :: ['type']


abstract: UNASSIGNED: The aim of the present study was to investigate the effect of @entity2993 combined with low-molecular-weight heparin (LMWH) on plasma early inflammatory cytokine levels as well as pulmonary pathophysiology of @entity35 with @entity295 . A total of 122 @entity35 were randomly divided into five groups including the sham operation group (n=10), @entity5976 group (n=10), @entity2993 group (n=34, 20 mg/kg/day), LMWH group (n=34, 100 IU/kg/day), and @entity2993 combined with LMWH group (n=34). Blood samples from 6 @entity35 in each group were collected to detect @entity1505 , @entity3426 and @entity22520 concentration in plasma by linked immunosorbent assay at baseline and postoperatively at 4, 8, 12 and 24 h. Pulmonary pathophysiology was observed postoperatively at 24 h. The remaining 10 @entity35 in each group were used to calculate the 7-day cumulative mortality rate. Compared to the sham operation group, the scores in @entity5976 were greater than those of the sham operation group (P<0.05). Compared to the @entity5976 group, the @entity295 severity scores of the @entity2993 , LMWH, and @entity2993 combined with LMWH groups decreased gradually. Significant difference was detected in the four groups (P<0.05 0.01). Compared to the sham operation group, at 4, 8, 12 and 24 h, the @entity1505 , @entity3426 and @entity22520 levels in plasma in @entity5976 increased significantly (P<0.01). Compared to the @entity5976 group, the @entity1505 , @entity3426 and @entity22520 levels of plasma in other groups decreased gradually, and there was a significant difference in the four groups (P<0.01). At 24 h post operation, compared to the sham operation group, the damage of pulmonary pathophysiology in @entity5976 was more severe. Compared to the @entity5976 group, the damage of pulmonary pathophysiology in other groups was slight. Compared to the @entity5976 group, the 7-day cumulative mortality rate in other groups decreased significantly (P<0.05). In conclusion, @entity2993 , combined with LMWH can decrease @entity295 severity, plasma inflammatory cytokine levels, pulmonary pathophysiology, and the 7-day cumulative mortality rate. @entity2993 , and LMWH may therefore be useful for the treatment of @entity295 due to its ability to inhibit the release of @entity1505 , @entity3426 and @entity22520 in septic @entity35 .

title: Effects of XXXX combined with low-molecular-weight heparin on plasma inflammatory cytokine level and pulmonary pathophysiology of @entity35 with @entity295 .

entities_list: @entity2993 :: ('MESH:C065179', 'Chemical') :: ['atorvastatin', 'Atorvastatin']

answer: @entity2993 :: (MESH:C065179,Chemical) :: ['atorvastatin']


abstract: Effects of essential @entity1718 on nerve conduction, @entity519 resistance, skeletal muscle contractile properties, and capillary density were examined in @entity3839 -induced @entity6 @entity35 . Nondiabetic and @entity6 controls and three @entity6 groups treated with 10% supplements of @entity4336 oil, evening primrose oil ( @entity27688 ), or a mixture of 80% evening primrose oil and 20% fish oil ( @entity27688 Marine) for 2 mo were used. @entity27688 and @entity27688 Marine increased plasma @entity18943 levels, but @entity1426 was elevated only with @entity27688 . @entity6 resulted in 15-29% reductions in sciatic motor and sensory saphenous nerve conduction velocity. @entity27688 prevented conduction deficits more effectively than @entity27688 Marine, and @entity4336 oil had no effect. In vitro measurement of sciatic nerve @entity519 resistance revealed a 49% increase in the time taken for action potential amplitude to decline by 50% with @entity6 . @entity4336 oil had no significant effect. With @entity27688 , @entity519 resistance was within the nondiabetic range. @entity27688 Marine produced intermediate results. Functional improvements may relate to enhanced vasa nervorum perfusion, because endoneurial capillary density increased by 22% with @entity27688 , angiogenesis perhaps resulting from @entity9610 production from @entity1426 . Soleus muscle contractions were prolonged by @entity6 . This was partially corrected by treatment, @entity27688 being most effective. Extensor digitorum longus muscle had reduced tetanic tension with @entity6 , and this was prevented by all treatments. Soleus showed a modest increase in capillarization with @entity27688 , which may have contributed to reduced susceptibility to fatigue. The data suggest involvement of abnormal @entity844 metabolism in the etiology of @entity3949 and @entity121 .

title: Essential @entity844 diet supplementation. Effects on peripheral nerve and skeletal muscle function and capillarization in @entity3839 -induced XXXX @entity35 .

entities_list: @entity844 :: ('CHEBI:35366', 'Chemical') :: ['fatty acid']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['Diabetes', 'diabetic', 'diabetes']

entities_list: @entity9610 :: ('CHEBI:23899', 'Chemical') :: ['eicosanoid']

entities_list: @entity3839 :: ('MESH:D013311', 'Chemical') :: ['streptozocin']

entities_list: @entity1426 :: ('MESH:D016718', 'Chemical') :: ['arachidonic acid']

entities_list: @entity3949 :: ('MESH:D003929', 'Disease') :: ['diabetic neuropathy']

entities_list: @entity18943 :: ('MESH:D017965', 'Chemical') :: ['gamma-linolenic acid']

entities_list: @entity1718 :: ('MESH:D005227', 'Chemical') :: ['fatty acids']

entities_list: @entity121 :: ('MESH:D009135', 'Disease') :: ['myopathy']

answer: @entity6 :: (MESH:D003920,Disease) :: ['diabetic']


abstract: BACKGROUND: @entity5631 in severe @entity447 precipitate physical, @entity2673 . OBJECTIVE: To compare the effects of secondary prophylaxis with on-demand @entity969 -formulated recombinant @entity2801 (rFVIII-FS) therapy in severe @entity447 . @entity1 AND METHODS: This open-label study included @entity1 aged 30-45 years with @entity2801 ( @entity2801 ) coagulant activity < 1 IU dL(-1) who were using on-demand @entity2801 treatment. @entity1 were treated with rFVIII-FS on demand for 6 months, followed by 7 months prophylaxis (20-40 IU kg(-1), three times per week, with the first month considered a run-in). The primary endpoint was the number of @entity5631 . RESULTS: Twenty @entity1 were enrolled (n = 19 completed); the mean age was 36.4 years, and 16 had @entity2720 . The median (25-75%) number of joint @entity548 decreased significantly with prophylaxis [0 (0-3)] vs. on-demand [15 (11-26); P < 0.001] therapy. The number of all @entity548 was 0 (0-3) vs. 20.5 (14-37; P < 0.001), respectively. Median (range) total Gilbert scores improved after prophylaxis [18 (3-39)] compared with on-demand [25 (4-46)] therapy, predominantly reflecting the improved bleeding score. Median time from last prophylactic infusion to bleed was 2 days; 82.5% of @entity548 occurred 2-3 days after the last infusion. Median 48-h and 72-h @entity2801 trough levels measured during months 10 and 13 were consistently > 6 and > 4 IU dL(-1), respectively. Treatment was well tolerated, and no inhibitor formation was observed. CONCLUSION: Secondary prophylaxis with rFVIII-FS significantly reduced the frequency of @entity5631 compared with on-demand therapy in adult @entity1 with severe @entity447 .

title: Efficacy and safety of secondary prophylactic vs. on-demand @entity969 -formulated recombinant XXXX treatment in adults with severe @entity447 : results from a 13-month crossover study.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'PATIENTS']

entities_list: @entity447 :: ('MESH:D006467', 'Disease') :: ['hemophilia', 'hemophilia A']

entities_list: @entity2673 :: ('MESH:C535569', 'Disease') :: ['psychosocial and financial difficulties']

entities_list: @entity969 :: ('MESH:D013395', 'Chemical') :: ['sucrose']

entities_list: @entity2720 :: ('MESH:D007592', 'Disease') :: ['target joints']

entities_list: @entity5631 :: ('MESH:D006395', 'Disease') :: ['hemarthroses', 'Hemarthroses']

answer: @entity2801 :: (2157,Gene) :: ['factor VIII']


abstract: The distinction of malignant @entity2615 from @entity420 with @entity456 is often difficult, even with electron microscopic and state-of-the-art histochemical and immunologic studies. We evaluated the DNA ploidy and cell cycle of 45 clinically, morphologically, and immunohistochemically well-characterized malignant @entity2615 to establish their ploidy profile and compared it with that of 41 @entity420 . All the cases were mucin negative and had been immunophenotyped with the following monoclonal antibodies: anti-keratin, anti-CEA, anti- @entity3111 , anti-HMFG2, Leu M1 ( @entity11823 ) and @entity19 . Single cell suspensions from the @entity982 blocks were prepared following Hedley's technique and were analyzed with a Coulter EPICS V flow cytometer. The resulting histograms were interpreted with the Multicycle software program. Five cases were excluded due to their high coefficients of variation. DNA @entity2007 was defined by the presence of more than one G0/G1 peak on the histograms obtained exclusively from the @entity5 sample. With this criterion, there is a possibility of missing aneuploid cases with a single aneuploid cycling population; however, fixatives and time of fixation produce such a remarkable variation in the fluorochrome uptake that any control, other than normal tissue present in the sample, was rendered unreliable. Five (14%) cases were DNA aneuploid with DNA indexes ranging from 1.2 to 1.9 (mean = 1.5). Three cases had increased S + G2/M values. Of the aneuploid cases, four were epithelial and one sarcomatous. In comparison, @entity2007 was found in 31 (75%) of the @entity2220 studied (p < 0.0001).(ABSTRACT TRUNCATED AT 250 WORDS)

title: DNA ploidy analysis of @entity2615 : its usefulness for their distinction from XXXX .

entities_list: @entity2007 :: ('MESH:D000782', 'Disease') :: ['aneuploidy']

entities_list: @entity2615 :: ('MESH:D008654', 'Disease') :: ['mesotheliomas']

entities_list: @entity982 :: ('MESH:D010232', 'Chemical') :: ['paraffin']

entities_list: @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinomas', 'pulmonary adenocarcinomas']

entities_list: @entity2220 :: ('MESH:C538231', 'Disease') :: ['lung adenocarcinomas']

entities_list: @entity456 :: ('MESH:D010995', 'Disease') :: ['pleural involvement']

answer: @entity2220 :: (MESH:C538231,Disease) :: ['lung adenocarcinomas']


abstract: OBJECT: Clinical studies use both disease-specific and generic health outcomes measures. Disease-specific measures focus on health domains most relevant to the clinical population, while generic measures assess overall health-related quality of life. There is little information about which domains of the @entity717 Index (ODI) are most important in determining improvement in overall health-related quality of life, as measured by the 36-Item Short Form Health Survey (SF-36), after lumbar spinal fusion. The objective of the study is to determine which clinical elements assessed by the ODI most influence improvement of overall health-related quality of life. METHODS: A single tertiary spine center database was used to identify @entity1 undergoing lumbar fusion for standard degenerative indications. @entity1 with complete preoperative and 2-year outcomes measures were included. Pearson correlation was used to assess the relationship between improvement in each item of the ODI with improvement in the SF-36 physical component summary (PCS) score, as well as achievement of the SF-36 PCS @entity922 ( @entity922 ). Multivariate regression modeling was used to examine which items of the ODI best predicted achievement for the SF-36 PCS @entity922 . The effect size and standardized response mean were calculated for each of the items of the ODI. RESULTS: A total of 1104 @entity1 met inclusion criteria (674 female and 430 male @entity1 ). The mean age at surgery was 57 years. All items of the ODI showed significant correlations with the change in SF-36 PCS score and achievement of @entity922 for the SF-36 PCS, but only @entity158 intensity, walking, and social life had r values > 0.4 reflecting moderate correlation. These 3 variables were also the dimensions that were independent predictors of the SF-36 PCS, and they were the only dimensions that had effect sizes and standardized response means that were moderate to large. CONCLUSIONS: Of the health dimensions measured by the ODI, @entity158 intensity, walking, and social life best predicted improvement in overall health-related quality of life, as measured using the SF-36 PCS.

title: Changes in the XXXX Index that predict improvement after lumbar fusion.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity717 :: ('MESH:D009069', 'Disease') :: ['Oswestry Disability']

entities_list: @entity922 :: ('MESH:D013568', 'Disease') :: ['minimum clinically important difference', 'MCID']

answer: @entity717 :: (MESH:D009069,Disease) :: ['Oswestry Disability']


abstract: The purpose of this study was to provide a better understanding of the regulatory role of the nuclear @entity134 receptor on the nuclear factor of kappa light polypeptide gene enhancer in B cells (NFkappaB) in @entity19 heart. NFkappaB regulates many nuclear genes and has been associated with many @entity1 @entity299 . NFkappaB's protein regulator gene, @entity1993 gene ( @entity1993 ), was found in this study to be regulated by peroxisome proliferator-activated receptors (PPARs). PPARs, retinoid X receptors (RXRs) and thyroid hormone receptors (THRs) are members of the nuclear receptor superfamily, which consists of a large number of transcription factors whose activities are regulated by their cognate ligands. These @entity134 hormone receptors are important regulators of gene expression and differentiation in the heart. These receptors form homo-(RXR, THR) and hetero-( @entity3229 -RXR, RXR-THR) dimers that bind DNA at various response elements ( @entity3229 , RXR and THR) in the promoter regions of target genes. The @entity3229 /RXR response elements in the promoter of @entity1993 are described in this article. A known @entity3229 activator ( @entity21372 ) and @entity3733 (vehicle) were introduced into control (FVB) and delta337T thyroid hormone receptor ( @entity9751 ) @entity19 . The delta337T @entity9751 transgenic @entity19 has a resistance to the thyroid hormone (RTH) phenotype. Affymetrix 430_2 chip gene expression was examined for four study groups (control, control with @entity21372 , delta337T @entity9751 and delta337T @entity9751 with @entity21372 ), consisting of seven @entity19 each. @entity1993 mRNA expression in the @entity21372 control and in @entity19 was upregulated significantly in microarray (P < 0.05) and quantitative RT-PCR (P < 0.01) analyses. The increase in mRNA level was also accompanied by an increase in @entity1993 protein in cells, as measured by Western blot analysis. Duplex oligo-DNAs containing the putative @entity3229 /RXR motif (AGGTCA/TCCAGT) from the @entity1993 promoter were used in gel shift assays to verify the binding of @entity3229 and RXR to their response elements. pGL4.0 [Luc] constructs of the @entity1993 promoter, with and without the @entity3229 /RXR motifs, were co-transfected with @entity19 @entity3229 , beta and gamma(1) into HepG2 cells and used in luciferase assays to verify gene activation. In conclusion, our study revealed that @entity3229 regulates the @entity19 cardiac @entity1993 gene in both control and transgenic @entity19 heart. The implications of this finding are discussed in relation to possible changes in cardiac function.

title: The XXXX gene is a peroxisome proliferator-activated receptor cardiac target gene.

entities_list: @entity19 :: ('10090', 'Species') :: ['mice', 'mouse', 'transgenic mice']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['cardiac diseases']

entities_list: @entity3733 :: ('MESH:D004121', 'Chemical') :: ['dimethylsulfoxide']

entities_list: @entity134 :: ('CHEBI:35341', 'Chemical') :: ['steroid']

entities_list: @entity1993 :: ('18035(Tax:10090)', 'Gene') :: ['IkappaBalpha', 'nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor alpha']

answer: @entity1993 :: (18035(Tax:10090),Gene) :: ['IkappaBalpha']


abstract: UNASSIGNED: Chemotherapy with @entity6023 such as @entity1311 ( @entity4045 ) is a key component of triple negative @entity0 (TNBC) treatment. @entity4045 is used in combination with other drugs in both the adjuvant setting and in advanced @entity0 . Since a proportion of @entity1 respond poorly to @entity4045 or relapse after its use, a greater understanding of the mechanisms conferring resistance to @entity4045 is required. One protein shown to be involved in drug resistance is @entity25536 ( @entity25536 ). High levels of @entity25536 have previously been associated with resistance to @entity4045 in TNBCs. In this study, we aimed to determine mechanisms by which @entity25536 confers @entity4045 resistance. We generated isogenic TNBC cell lines that differed by @entity25536 levels and treated these with @entity4045 . Using microarray analysis, we identified @entity5738 as a potential target of @entity25536 . We found that low @entity5738 mRNA levels are associated with poor @entity0 @entity1 prognosis, and that @entity5738 and @entity25536 mRNA expression was inversely correlated in a TNBC line and in a proportion of @entity0 . Reducing the levels of @entity5738 caused TNBC cells to become more resistant to @entity4045 . Given that @entity4045 targets cycling cells, we propose a model whereby high @entity25536 levels in some TNBC cells can lead to reduced levels of @entity5738 , which in turn promotes slow cell cycling and resistance to @entity4045 . Therefore @entity25536 and @entity5738 levels are biologically linked and may provide a biomarker for TNBC response to @entity4045 . This article is protected by copyright. All rights reserved.

title: A novel @entity5738 dependent mechanism for XXXX modulation of @entity1311 response in a triple negative @entity0 cell line.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['TNBC tumours', 'breast cancer']

entities_list: @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel']

answer: @entity25536 :: (4904,Gene) :: ['YB-1']


abstract: BACKGROUND: @entity384 is the primary indication for heart transplantation in @entity1 beyond infancy. Although beta-blockers improve symptoms, ejection fraction, and survival in adults with @entity712 , little is known of their effects in @entity1 . METHODS: This study reviews our pediatric experience with the beta-blocker, @entity1406 , at 3 institutions. We gave @entity1406 to 15 @entity1 , age 8.6 +/- 1.3 years (range 2.5 to 15 years), with @entity1000 (n = 9), @entity4349 @entity296 (n = 3), and @entity1555 , @entity296 , and post-surgical @entity296 (n = 1 each). All had been treated with conventional medications (digoxin, diuretics, and ACE inhibitors) for 22.5 +/- 9 months before starting @entity1406 . @entity1406 was started at 0.1 to 0.2 mg/kg/ dose given twice daily and slowly increased over a period of weeks to a dose of 1.1 +/- 0.1 mg/kg/day (range 0.5 to 2.3 mg/kg/day). RESULTS: Between the time point of stabilization on conventional medications and the initiation of @entity1406 therapy, there was no significant change in fractional shortening (13.1 +/- 1.2% vs 15.0 +/- 1.2%) or ejection fraction (25.6 +/- 2.1% vs 27.0 +/- 3.4%). However, after @entity1406 therapy for 23.2 +/- 7 months, there was a significant increase in fractional shortening(23.3 +/- 2.6%) and ejection fraction (41.1 +/- 4.3%) (p < 0.05). CONCLUSIONS: @entity1406 improves ventricular function in some @entity1 with @entity384 and @entity712 . Further study is warranted to better define which @entity1 may benefit most from beta-blocker therapy and which beta-blockers are most efficacious.

title: Beta-blocker treatment of XXXX with @entity712 in @entity1 : a multi-institutional experience.

entities_list: @entity1 :: ('9606', 'Species') :: ['children']

entities_list: @entity712 :: ('MESH:D006333', 'Disease') :: ['congestive heart failure']

entities_list: @entity296 :: ('MESH:D009202', 'Disease') :: ['cardiomyopathy', 'postmyocarditis cardiomyopathy']

entities_list: @entity4349 :: ('CHEBI:48120', 'Chemical') :: ['anthracycline']

entities_list: @entity384 :: ('MESH:D002311', 'Disease') :: ['Dilated cardiomyopathy', 'dilated cardiomyopathy']

entities_list: @entity1406 :: ('MESH:D008790', 'Chemical') :: ['metoprolol', 'Metoprolol']

entities_list: @entity1000 :: ('MESH:C536277', 'Disease') :: ['idiopathic dilated cardiomyopathy']

entities_list: @entity1555 :: ('MESH:D020388', 'Disease') :: ['Duchenne muscular dystrophy cardiomyopathy']

answer: @entity384 :: (MESH:D002311,Disease) :: ['dilated cardiomyopathy']


abstract: @entity3219 in South America is associated with @entity791 in 70-90 % of cases. It is visceral and cutaneous, compromising the oral, pharynx, and laryngeal mucous membranes. The involvement of the nasal mucosa is unusual. Two @entity1 with perforation of the nasal septum as the only sign of their disease were clinically and histopathologically diagnosed as @entity232 . The revision of the biopsies and the culture of nasal discharge secretions showed that the pathogens seen were not amastigotes but @entity3218 . Other @entity75 were not detected, nor there was history of @entity4536 . The leishmanin skin test, available only for the male @entity1 , was negative. The PCR and immunofluorescence antibody titers for Leishmania were negative in both @entity1 . They were @entity645 positive; in the male, his CD4+ T cell count was 60/mm(3) and in the female 133/mm(3). The nasal ulcer was the only manifestation of @entity3219 and the first of @entity791 in both @entity1 . The male @entity1 recovered with @entity2379 and @entity2059 treatment. The female has improved with @entity2059 . Both patients received antiretroviral treatment. Nasal mucous membrane @entity1066 should include @entity3219 among the differential diagnosis. In conclusion, two @entity1 had perforation of their nasal septum as the only manifestation of @entity3219 , a diagnosis confirmed by nasal mucosa biopsy and by culture of @entity3218 , findings which demonstrated that both @entity1 had @entity791 .

title: Perforation of the nasal septum as the first sign of XXXX associated with @entity791 and review of published literature.

entities_list: @entity2379 :: ('MESH:D000666', 'Chemical') :: ['amphotericin B']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['mycotic lesions']

entities_list: @entity232 :: ('MESH:D007896', 'Disease') :: ['leishmaniasis']

entities_list: @entity4536 :: ('MESH:D016773', 'Disease') :: ['cutaneous leishmaniasis']

entities_list: @entity3218 :: ('5037', 'Species') :: ['Histoplasma capsulatum', 'H. capsulatum']

entities_list: @entity3219 :: ('MESH:D006660', 'Disease') :: ['histoplasmosis', 'Disseminated histoplasmosis']

entities_list: @entity2059 :: ('MESH:D017964', 'Chemical') :: ['itraconazole']

answer: @entity3219 :: (MESH:D006660,Disease) :: ['histoplasmosis']


abstract: The @entity35 double-SAH model is one of the standard models to simulate delayed @entity2553 ( @entity2553 ) in @entity1 . However, the proof of delayed @entity63 @entity75 is missing so far. Our objective was, therefore, to determine histological changes in correlation with the development of symptomatic and perfusion weighted imaging (PWI) proven @entity2553 in this animal model. @entity2553 was induced by injection of autologous blood in the cisterna magna of 22 @entity35 . Histological changes were analyzed on day 3 and day 5. Cerebral blood flow (CBF) was assessed by PWI at 3 tesla magnetic resonance (MR) tomography. Neuronal cell count did not differ between sham operated and SAH @entity35 in the hippocampus and the cerebral cortex on day 3. In contrast, on day 5 after SAH the neuronal cell count was significantly reduced in the hippocampus (p<0.001) and the inner cortical layer (p=0.03). The present investigation provides quantitative data on brain tissue damage in association with delayed @entity2553 for the first time in a @entity35 SAH model. Accordingly, our data suggest that the @entity35 double-SAH model may be suitable to mimic delayed @entity63 @entity75 due to @entity2553 and to investigate the neuroprotective effects of drugs.

title: Histological evidence of delayed XXXX brain tissue damage in the @entity35 double-hemorrhage model.

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemic']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['brain damage']

entities_list: @entity35 :: ('10116', 'Species') :: ['rat', 'Sprague-Dawley rats', 'rats']

entities_list: @entity2553 :: ('MESH:D020301', 'Disease') :: ['cerebral vasospasm', 'CVS']

answer: @entity63 :: (MESH:D007511,Disease) :: ['ischemic']


abstract: INTRODUCTION: The cold shock @entity25536 ( @entity25536 ) fulfills important roles in regulating cell proliferation and differentiation. Overexpression occurs in various @entity5 cells. Given the existence of extracellular @entity25536 we set out to determine the diagnostic, predictive and prognostic role of serum @entity25536 / @entity7818 for @entity1 with @entity43 (EOC). METHODS: The protein fragment @entity25536 / @entity7818 was quantified by sandwich ELISA in serum samples from 132 healthy female volunteers and 206 @entity1 with histological diagnosis of primary EOC. The ELISA sensitivity and specificity to detect EOC were calculated using receiver operating curves. Survival data were calculated using Kaplan Maier curves. RESULTS: Median age at the time of diagnosis was 60years and follow-up ended with a mean of 44.8month. 188 (91%) @entity1 were diagnosed at advanced stages (FIGO III/IV) and 188 @entity1 (91%) suffered from high-grade serous @entity43 . @entity25536 / @entity7818 levels were significantly decreased in older @entity1 (p=0.021). Significantly lower serum levels of @entity25536 / @entity7818 were detected in the EOC cohort when compared to the control group (p<0.0001, AUC=0.827; 95% CI, 0.787-0.867). Using the expression of serum @entity25536 / @entity7818 in early stages I and II cases these could be differentiated from control cases (p<0.0001, AUC=0.816; 95% CI 0.704-0.929). No other significant associations between clinical prognostic factors and @entity25536 / @entity7818 serum levels were detected. Immunoblotting results with serum samples suggest that masking of epitopes by the @entity25536 / @entity7818 fragment in multiprotein-complexes under non reducing conditions leads to the observed reduced ELISA readings in the EOC cohort. CONCLUSIONS: The quantification of fragment @entity25536 / @entity7818 derived from cold shock protein @entity25536 in serum samples could be useful for the early diagnosis of EOC.

title: Y-box protein-1/ @entity7818 as novel serum marker for @entity43 diagnosis: A study by the XXXX ( @entity43 ).

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian carcinoma', 'primary epithelial ovarian cancer']

answer: @entity43 :: (MESH:D010051,Disease) :: ['Tumor Bank Ovarian Cancer']


abstract: OBJECTIVES: In this study we sought to explore the relationship between cardiac magnetic resonance (CMR) with late @entity2287 enhancement (LGE) and histopathological parameters including @entity82 and replacement @entity82 (scar) in @entity1 with @entity1121 ( @entity1121 ). BACKGROUND: CMR-LGE is a well-established tool for the assessment of scar in @entity741 . Its role in @entity1121 has evolved in recent years, and an association with nonsustained @entity1165 has been demonstrated. METHODS: @entity1121 @entity1 who underwent septal myectomy during the period 2004 through 2010 and had undergone CMR-LGE no more than 6 months before surgery were selected. Histopathological assessment of the myectomy specimens included quantitative digital analysis (interstitial and replacement @entity82 ) and semiquantitative assessment (small intramural coronary arteriole @entity1141 and disarray). Correlations between CMR-LGE measured with various techniques, @entity168 above the signal intensity for the normal remote myocardium (2, 4, 5, 6, and 10 @entity168 ) and the full width at half maximum (FWHM) technique, at the myectomy site, and @entity82 , replacement @entity82 (scar), and their sum ( @entity82 + scar) were evaluated. RESULTS: Twenty-nine @entity1 were included. Statistically significant correlations between CMR-LGE (at 2, 4, 5, 6, 10 @entity168 and by the FWHM technique), and both @entity82 and the combined interstitial and replacement @entity82 were found. The strongest correlation was between combined interstitial and replacement @entity82 and CMR-LGE measured at 5 @entity168 (r = 0.78, p < 0.0001). LGE measured at 10 @entity168 demonstrated the best correlation with replacement @entity82 (r = 0.42, p = 0.02). Bland-Altman analysis revealed optimum agreement between the combined interstitial and replacement @entity82 found at pathology and LGE measured at 4 @entity168 . In addition, moderate and severe small intramural @entity453 showed a statistically significant correlation with replacement @entity82 (p = 0.01) and CMR-LGE at 10 @entity168 (p = 0.04). CONCLUSIONS: CMR-LGE measured at 4 @entity168 and 5 @entity168 yields the closest approximation to the extent of total @entity82 measured by the histopathological standard of reference. These findings have implications for future investigations of CMR-LGE and its association with important clinical endpoints in @entity1121 , including @entity1164 .

title: Myocardial fibrosis in XXXX : accurate reflection of histopathological findings by CMR.

entities_list: @entity1164 :: ('MESH:D016757', 'Disease') :: ['sudden cardiac death']

entities_list: @entity82 :: ('MESH:D005355', 'Disease') :: ['interstitial fibrosis', 'fibrosis']

entities_list: @entity1165 :: ('MESH:D017180', 'Disease') :: ['ventricular tachycardia']

entities_list: @entity1121 :: ('MESH:D002312', 'Disease') :: ['HCM', 'hypertrophic cardiomyopathy']

entities_list: @entity741 :: ('MESH:D017202', 'Disease') :: ['ischemic heart disease']

entities_list: @entity453 :: ('MESH:D003324', 'Disease') :: ['coronary artery dysplasia']

entities_list: @entity2287 :: ('MESH:D005682', 'Chemical') :: ['gadolinium']

entities_list: @entity1141 :: ('MESH:C535662', 'Disease') :: ['dysplasia']

answer: @entity1121 :: (MESH:D002312,Disease) :: ['hypertrophic cardiomyopathy']


abstract: PURPOSE: In 2007, we published our initial experience in treating inoperable @entity1149 ( @entity1149 ) with intensity-modulated radiation therapy (IMRT). The current report is an update of that experience with long-term follow-up. METHODS AND MATERIALS: @entity1 in this retrospective review were 165 @entity1 who began definitive radiotherapy, with or without chemotherapy, for newly diagnosed, pathologically confirmed @entity1149 to a dose of >= 60 Gy from 2005 to 2006. Early and late @entity137 assessed included treatment-related @entity55 (TRP), @entity3794 , @entity2910 , and esophageal stricture, scored mainly according to the Common Terminology Criteria for Adverse Events 3.0. Other variables monitored were radiation-associated @entity1909 and changes in body weight and Karnofsky performance status. The Kaplan-Meier method was used to compute survival and freedom from radiation-related acute and late @entity137 as a function of time. RESULTS: Most @entity1 (89%) had Stage III to IV disease. The median radiation dose was 66 Gy given in 33 fractions (range, 60-76 Gy, 1.8-2.3 Gy per fraction). Median overall survival time was 1.8 years; the 2-year and 3-year overall survival rates were 46% and 30%. Rates of Grade >= 3 maximum TRP (TRP(max)) were 11% at 6 months and 14% at 12 months. At 18 months, 86% of @entity1 had developed Grade >= 1 maximum @entity3794 ( @entity3794 (max)) and 7% Grade >= 2 @entity3794 (max). The median times to maximum @entity2910 ( @entity2910 (max)) were 3 weeks (range, 1-13 weeks) for Grade 2 and 6 weeks (range, 3-13 weeks) for Grade 3. A higher percentage of @entity1 who experienced Grade 3 @entity2910 (max) later developed Grade 2 to 3 esophageal stricture. CONCLUSIONS: In our experience, using IMRT to treat @entity1149 leads to low rates of @entity358 , and favorable clinical outcomes in terms of survival.

title: Long-term clinical outcome of intensity-modulated radiotherapy for inoperable XXXX : the MD Anderson experience.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicities']

entities_list: @entity55 :: ('MESH:D011014', 'Disease') :: ['pneumonitis']

entities_list: @entity2910 :: ('MESH:D004941', 'Disease') :: ['esophagitis']

entities_list: @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small-cell lung cancer']

entities_list: @entity3794 :: ('MESH:D011658', 'Disease') :: ['pulmonary fibrosis']

entities_list: @entity358 :: ('MESH:D008171', 'Disease') :: ['pulmonary and esophageal toxicity']

entities_list: @entity1909 :: ('MESH:D003872', 'Disease') :: ['dermatitis']

answer: @entity1149 :: (MESH:D002289,Disease) :: ['non-small cell lung cancer']


abstract: Operative management of @entity1 presenting @entity1358 ( @entity1358 ) with right @entity5 thrombus extension is a technical challenge. It requires the use of cardiopulmonary bypass (CPB). The aim of this study was to report our early experience and to describe a simplified CPB technique. 5 consecutive @entity1 underwent surgical resection by a joint cardiovascular and urological team. The ascending aorta was canulated. The venous drainage was achieved using a proximal canula inserted in the superior vena cava and a distal canula inserted in the IVC below the renal veins. Right atrium thrombus extension was extracted under normothermic CPB without cross clamping or @entity1167 . A cavotomy was performed at the ostium of the renal vein and an endoluminal occlusion catheter was introduced. The thrombectomy and the radical nephrectomy were then performed. The occurrence of @entity12464 , operative time, perioperative @entity548 , and post-operative complications were assessed. Mean @entity1 age was 62.9 years. Atrial and caval thrombectomy were achieved successfully in all @entity1 . Mean operative time was 206 min. Mean CPB time was 62 min. Mean hospital stay was 18.8 days. One @entity204 occurred, due to @entity1576 . An asymptomatic early @entity715 of the IVC was diagnosed by CT scan in 1 @entity1 . The four remaining @entity1 were alive 6 months after the surgical procedure. Minimally invasive CPB technique can be used to treat intra @entity5 extension arising from @entity1358 . It can be performed safely with acceptable complications rate.

title: Surgical treatment of XXXX with @entity715 : early experience and description of a simplified technique.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding']

entities_list: @entity12464 :: ('MESH:D009360', 'Disease') :: ['gaseous or tumor embolism']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['atrial thrombus tumor', 'atrial tumor']

entities_list: @entity1358 :: ('MESH:D002292', 'Disease') :: ['renal cell carcinoma', "renal cell carcinoma's", 'RCC']

entities_list: @entity1576 :: ('MESH:D012131', 'Disease') :: ['respiratory failure']

entities_list: @entity1167 :: ('MESH:D006323', 'Disease') :: ['cardioplegic arrest']

entities_list: @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombosis']

answer: @entity1358 :: (MESH:D002292,Disease) :: ['renal cell carcinoma']


abstract: @entity3810 ( @entity3727 ) is frequently used for maintenance of anesthesia in research animals because of its minimal effect upon circulatory variables and the ability to rapidly alter its anesthetic concentration. However, @entity3727 's low anesthetic potency may result in inadequate levels of anesthesia under experimental conditions; thus, the ability of @entity3727 to provide adequate anesthesia during tracheal stimulation in @entity35 , following withdrawal of @entity1508 was evaluated. Twenty @entity35 of similar ages and weights were anesthetized with @entity1508 (1.44% inspired) and their tracheas orally intubated. Ten minutes prior to the conclusion of a 90-min @entity1508 stabilization period, either 70% @entity3727 (n = 10) or 70% @entity1568 (n = 10) was added to the inspired anesthetic gas mixture. The @entity1508 was discontinued at the conclusion of the 90-min period and each @entity35 was observed for spontaneous motor behavior while end-expiratory anesthetic gases were intermittently measured with mass spectrometry. The @entity1508 concentrations present at the times of four specific, consistently occurring behaviors were measured, and comparisons were made between the @entity3727 and @entity1568 groups by a mean t test. There were no significant differences (P less than 0.05) in the @entity1508 concentration between the @entity3727 and @entity1568 groups in three of the four behaviors compared: 1) change in respiratory pattern, 2) purposeful movement of the torso, and 3) purposeful self-extubation. In the fourth behavior (purposeful movement of an extremity) the @entity1508 concentration was higher in the @entity3727 group than in the @entity1568 group. A mean @entity1508 concentration of 0.49% was required to prevent the purposeful behaviors in the presence of @entity3727 .(ABSTRACT TRUNCATED AT 250 WORDS)

title: Insufficient anesthetic potency of @entity3810 in the XXXX .

entities_list: @entity1568 :: ('MESH:D009584', 'Chemical') :: ['nitrogen']

entities_list: @entity1508 :: ('MESH:D006221', 'Chemical') :: ['halothane']

entities_list: @entity3810 :: ('MESH:D009609', 'Chemical') :: ['Nitrous oxide']

answer: @entity35 :: (10116,Species) :: ['rat']


abstract: BACKGROUND: Leprosy often heals with residual @entity272 after completion of treatment. WHO recommends fixed duration @entity6371 ( @entity6371 ) irrespective of whether lesions clear or persist after treatment. @entity1 with @entity75 are often unsatisfied and may undergo repeat biopsy and re-treatment. This study was conducted to compare the clinicohistopathological features in @entity5117 before and after @entity6371 from September 2012 to February 2014. METHODS: Sixty-one untreated cases of @entity5117 were investigated and given standard WHO paucibacillary- @entity6371 for 6 months. Scoring of clinical activity was done; histopathological activity was graded according to @entity738 fraction. Forty-four @entity1 who completed the treatment were subjected to post-treatment biopsy. Clinical response to therapy was graded as active, resolving and inactive and histopathological changes were compared in all @entity1 . RESULTS: Among the 44 @entity1 , the lesions were inactive, resolving and active in 39% (17/44), 39% (17/44) and 23% (10/44) of @entity1 respectively. Histologically, disease was inactive, resolving and active in 30% (13/44), 9% (4/44) and 61% (27/44). But histomorphological features suggesting regression: loose @entity738 (59%, 26/44); lymphocyte predominance (66%, 29/44); vacuolar change in epithelioid cell cytoplasm (59%, 26/44), were statistically significant in post-treatment compared to pre-treatment. CONCLUSIONS: Although histological resolution is slower than clinical resolution, qualitative histomorphological changes in correlation with clinical inactivity can offer a fair suggestion to the clinician to terminate therapy.

title: Clinical and histopathological features of @entity5117 before and after XXXX : a prospective study.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity5117 :: ('MESH:D056005', 'Disease') :: ['paucibacillary leprosy']

entities_list: @entity6371 :: ('MESH:D018088', 'Disease') :: ['multidrug therapy', 'MDT']

entities_list: @entity738 :: ('MESH:D006099', 'Disease') :: ['granulomas', 'granuloma']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['residual lesions']

entities_list: @entity272 :: ('MESH:D012871', 'Disease') :: ['skin lesions']

answer: @entity6371 :: (MESH:D018088,Disease) :: ['multidrug therapy']


abstract: OBJECTIVE: To investigate the value of gene analysis of amniotic fluid exfoliated cells and @entity13308 detection from cord blood in prenatal diagnosis of high-risk fetus with @entity17454 . METHOD: Seven @entity1 with @entity17454 were diagnosed by gene analysis and @entity13308 detected by flow cytometry from 2008 to 2010. After detailed inquiry for medical history and gene analysis of related family members, seven pedigree trees were drawn, including 15 carriers of abnormal genes. From 2008 to 2011, seven samples of amniotic cell gotten by amniocentesis were collected from seven high-risk pregnant @entity1 with abnormal gene during 18 to 20 gestational weeks. @entity13308 gene was amplified by polymerase chain reaction (PCR) from DNA of amniotic cell gotten and sequencing was performed directly on the PCR products forward and reversely. Embryo blood sample was collected from one high-risk fetus by needle puncture of umbilical blood vessel and @entity13308 expression was detected by flow cytometry. Karyotyping was performed in amniotic cell gotten cultivated by orthotopic slice and G band staining. Gene analysis of @entity13308 , @entity13308 expression detected by flow cytometry and evaluation of immune function were reexamined in high-risk fetus after delivery. RESULT: Amniocentesis and culture of amniotic cell succeeded in all the seven fetuses. Gene analysis and karyotyping showed that one male fetus and four female fetuses were normal and two female fetuses were carriers. @entity13308 expression detected from embryo blood sample of the @entity1 was normal. After delivery, the result of gene analysis, @entity13308 detection and evaluation of immune function was the same as that of prenatal diagnosis. CONCLUSION: Karyotyping, gene analysis and @entity13308 detection of cord blood can provide reliable service of prenatal diagnosis for high-risk pregnant @entity1 with @entity17454 .

title: [Analysis of prenatal diagnosis for seven high-risk fetuses with XXXX ].

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'patient']

entities_list: @entity17454 :: ('MESH:D014923', 'Disease') :: ['Wiskott-Aldrich syndrome']

answer: @entity17454 :: (MESH:D014923,Disease) :: ['Wiskott-Aldrich syndrome']


abstract: @entity2918 (PGs) play an important role in parturition in many species, including @entity1 . The present study examined the distribution of PG receptor subtypes ( @entity7700 -4 and FP) in intrauterine tissues at term and @entity600 . Placentas and fetal membranes were collected from @entity1 at term in labour (n = 12) or not in labour (n = 12). Preterm tissue was collected from three different groups of @entity1 : (1) @entity3762 (PTL) without @entity5870 or @entity5935 (BM) treatment (n = 9), (2) idiopathic PTL that received BM with no @entity5870 (PTL-BM; n = 9) and (3) pregnancies that were complicated with @entity5870 and had no BM (PTL- @entity23012 ; n = 6). @entity7700 -4 and FP receptors were localised and levels of expression were determined by western blot analysis. All EP receptors and FP were localised to the amnion, placenta and choriodecidua. Moreover, isolated amnion mesenchymal, amnion epithelial, chorion trophoblast and syncytiotrophoblast cells in primary culture also expressed PG receptors. A significant increase was observed in @entity7700 , @entity7699 and FP expression in placenta, chorion and amnion with labour. Maternal @entity5935 treatment increased @entity7700 , @entity7699 and FP receptor protein expression and @entity5870 decreased expression in all the receptor subtypes. These changes in PG receptors in the fetal membranes are consistent with the development of a feed-forwards cascade mediated through PG action that may contribute to the birth process.

title: Expression and regulation of prostaglandin receptors in the XXXX placenta and fetal membranes at term and preterm.

entities_list: @entity1 :: ('9606', 'Species') :: ['humans', 'patients']

entities_list: @entity5935 :: ('MESH:D001623', 'Chemical') :: ['betamethasone']

entities_list: @entity5870 :: ('MESH:D002821', 'Disease') :: ['chorioamnionitis']

entities_list: @entity2918 :: ('MESH:D011453', 'Chemical') :: ['Prostaglandins']

entities_list: @entity600 :: ('MESH:D000014', 'Disease') :: ['preterm birth']

entities_list: @entity3762 :: ('MESH:C562694', 'Disease') :: ['idiopathic preterm labour']

answer: @entity1 :: (9606,Species) :: ['human']


abstract: @entity470 ( @entity470 ) mutations are common in lung @entity420 , especially from nonsmoking @entity1 of Asian descent. We have previously shown @entity470 mutations occur in >70% of @entity2220 from nonsmokers in our population with a complex mutational profile, including 13% of @entity470 double mutations. In this study, we investigated the in vitro @entity4562 response of four @entity470 double mutants identified in untreated @entity1 , including @entity26011 + @entity9512 , @entity26012 + @entity26013 , @entity9513 + @entity9512 , and @entity26014 + @entity9512 . The phosphorylation profiles of @entity470 and downstream effectors @entity584 , @entity26015 , and @entity1366 were compared by immunoblot analyses among the single and double mutants transfected into H358 cells. Results showed that mutants responded to in vitro @entity4562 treatment with different sensitivities. The @entity26013 and @entity9512 single mutants showed the highest @entity4562 sensitivity compared with the corresponding coexisting single mutants @entity26012 , @entity26011 , @entity26014 , and @entity9513 . The double mutants @entity26012 + @entity26013 , @entity26011 + @entity9512 , and @entity26014 + @entity9512 showed attenuated responses to @entity4562 in the @entity470 and downstream effector phosphorylation profiles compared with @entity26013 or @entity9512 alone. @entity9513 + @entity9512 showed strong resistance to @entity4562 . Clinically, the @entity1 whose @entity5 contained @entity26014 + @entity9512 showed @entity5 stabilization by 250 mg oral @entity4562 daily but cerebral metastasis developed 6 months later. Correlation with the in vitro phosphorylation profile of @entity26014 + @entity9512 suggested that treatment failure was probably due to inadequate suppression of @entity470 signaling by the drug level attainable in the cerebrospinal fluid at the given oral dosage. Overall, the findings suggested that rare types of @entity470 substitution mutations could confer relative @entity4562 resistance when combined with the common activating mutants.

title: Double XXXX mutants containing rare @entity470 mutant types show reduced in vitro response to @entity4562 compared with common activating missense mutations.

entities_list: @entity4562 :: ('MESH:C419708', 'Chemical') :: ['gefitinib']

entities_list: @entity470 :: ('1956', 'Gene') :: ['Epidermal growth factor receptor', 'EGFR']

entities_list: @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinomas']

entities_list: @entity2220 :: ('MESH:C538231', 'Disease') :: ['lung adenocarcinoma']

answer: @entity470 :: (1956,Gene) :: ['EGFR']


abstract: INTRODUCTION: @entity15 ( @entity15 ) mainly affects @entity1 of fertile age. To date, the only recommendation for @entity1 with @entity15 intending to become pregnant is to stop all treatment. This recommendation reflects the concerns about the effects of @entity66 ( @entity66 ) on the offspring. The objective of the present study was to assess the potential long-term effects of maternal exposure to @entity66 on the offspring. METHOD: This was a retrospective study revising medical data on the offspring of @entity1 with @entity15 . These @entity1 now have @entity1 aged at least 1 year and include a group of @entity1 that were not exposed to any @entity66 for at least 3 months prior to pregnancy and during the whole gestation (control group). Another group of @entity1 had at least 2 weeks of exposure to @entity66 , mainly to interferon beta or glatiramer acetate RESULTS: The @entity1 with @entity15 participating in this study have @entity1 currently aged, on average, 6.6 years (range 1-39 years). There was no pattern of drug-related adverse events or complications in the @entity1 whose mothers were exposed to @entity66 . No specific long-term adverse events were observed in the offspring of @entity1 with @entity15 who were exposed to drugs during pregnancy. The profile of relevant diagnoses in their @entity1 was similar to that of @entity1 whose mothers had not been exposed to @entity66 . CONCLUSIONS: The present retrospective study did not show a specific profile of long-term deleterious drug effects on @entity1 born from mothers who were exposed to drugs for @entity15 treatment.

title: Long-term effects of exposure to XXXX in the offspring of mothers with @entity15 : a retrospective chart review.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'children', 'patients']

entities_list: @entity15 :: ('MESH:D009103', 'Disease') :: ['Multiple sclerosis', 'MS']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['disease-modifying drugs', 'DMDs']

answer: @entity66 :: (MESH:D004194,Disease) :: ['disease-modifying drugs']


abstract: After discontinuation of neuroleptic agents, their effects are still present for a long time. The exact underlaying mechanisms are still unclear. In two previous studies we measured the concentrations and region-specific distribution of @entity1767 (Kornhuber et al. 1999) and @entity9874 (Kornhuber et al. 2006) in postmortem @entity1 brain tissues. The aim of the present paper is to compare the results of these two studies. Even after short-term treatment, @entity1767 and @entity9874 concentrations reach high levels in @entity1 brain tissue. @entity1767 concentrations in brain tissue are 10-30 times higher than the optimum serum concentrations in the treatment of @entity161 . The brain-to-blood concentration ratio of @entity9874 is about 10. The estimated elimination half-life of these drugs in brain tissue are 6.8 days ( @entity1767 ), 7.9 days ( @entity9874 ) and 27.8 days for the metabolite desmethyl- @entity9874 , respectively. After two half-lives (about 2 weeks), a considerable amount of drug remains in brain tissue. @entity1767 concentrations appeared to be homogeneously distributed across different brain areas, whereas @entity9874 shows a region-specific distribution, with highest values in the basal ganglia. The persistence of neuroleptic drugs in the @entity1 brain might explain their prolonged effects and side effects. The region-specific distribution of @entity9874 may increase our understanding of both the preferential @entity137 of neuroleptic drugs against basal ganglia structures and higher basal ganglia volumes in @entity1 treated with neuroleptics.

title: Neuroleptic drugs in the XXXX brain: clinical impact of persistence and region-specific distribution.

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patients']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity161 :: ('MESH:D012559', 'Disease') :: ['schizophrenia']

entities_list: @entity1767 :: ('MESH:D006220', 'Chemical') :: ['haloperidol', 'Haloperidol']

entities_list: @entity9874 :: ('MESH:D008728', 'Chemical') :: ['levomepromazine']

answer: @entity1 :: (9606,Species) :: ['human']


abstract: @entity7049 ( @entity15274 ) microfibrous scaffolds with three-dimensional (3D) structures were fabricated using an electrospinning technique with a subsequent mechanical expansion process. To achieve a 3D fibrous structure, the fusion at the contact points of the as-spun @entity15274 microfibers was avoided using an appropriate binary solvent system of @entity1044 and @entity1324 . The solvent composition was optimized based on the solvent power, volatility, and viscosity ( @entity1044 : @entity1324 = 9:1 volume ratio). The final 3D structure of the electrospun scaffolds was obtained after mechanical expansion of the electrospun microfibrous mats. The pore sizes of the scaffolds were controlled by varying the degree of expansion of the nonbonded microfibrous mats, and they were in the range of several microns up to 400  m. The 3D scaffolds were examined for their morphological properties and their potential use for the proliferation of osteoblasts. Generally recognized electrospun 2D nanofibrous membranes were also tested in order to compare the cell behaviors using different scaffold geometries. The 3D scaffolds demonstrated a high level of osteoblast proliferation (1.8-fold higher than nanofibrous membranes in a week). The osteoblasts actively penetrated the inside of the 3D scaffold and showed a spatial cell distribution, as confirmed by SEM and H_E staining, while a monolayer formed in the case of the 2D nanofibrous membranes with limited cell infiltration. In vivo results further showed that 3D electrospun microfibrous matrices were a favorable substrate for cell infiltration and bone formation after 2 and 4 weeks, using a @entity95 @entity9332 model. In this study, the 3D microfibrous @entity15274 scaffolds fabricated using electrospinning techniques might be an innovative addition to tissue engineering applications.

title: Novel three-dimensional scaffolds of XXXX microfibers using electrospinning and mechanical expansion: Fabrication and bone regeneration.

entities_list: @entity1044 :: ('MESH:D008752', 'Chemical') :: ['methylene chloride']

entities_list: @entity9332 :: ('MESH:C537963', 'Disease') :: ['calvarial defect']

entities_list: @entity7049 :: ('MESH:C010506', 'Chemical') :: ['Poly(L-lactic acid)']

answer: @entity7049 :: (MESH:C010506,Chemical) :: ['poly(L-lactic acid)']


abstract: BACKGROUND: The transanal pull-through has become the standard operation for @entity1963 in many pediatric surgical centers. Over the past 8 years, we have modified our technique by leaving a short-rather than a long-rectal cuff and by doing routine intraabdominal colonic biopsies through an umbilical incision before beginning the anal dissection. The aim of this study was to determine if these modifications have changed the outcome for @entity1 undergoing this operation. METHODS: A retrospective cohort study of all @entity1 who underwent transanal pull-through by a single surgeon between 1997 and 2005 was conducted. RESULTS: There were 23 @entity1 who had a long cuff (10-15 cm) and 22 who had a short cuff (<2 cm). The short cuff group tended to be younger (25 +/- 23 vs 139 +/- 67 days; P < .05) and smaller (3.5 +/- 0.7 vs 6.0 +/- 2.7 kg; P < .05) at the time of surgery. The operating time was shorter (167 vs 186 minutes; P = .05) in the short cuff group. Outcomes were improved in the short cuff group, as evidenced by decreased hospital stay (1.9 +/- 0.6 vs 2.7 +/- 0.9; P < .05), decreased incidence of @entity1964 (9% vs 30%; P = .1), and lower incidence of narrowing requiring daily dilatations (5% vs 30%; P < .05). Preliminary colonic biopsy was performed on 18 of the 45 @entity1 . This had no significant effect on narcotic use (66% vs 70%; P = .8) and did not increase operating time (174 +/- 31 vs 179 +/- 34 minutes; P = .6). Hospital stay was shorter in the umbilical biopsy group (1.9 +/- 0.6 vs 2.6 +/- 0.9 days; P = .006). CONCLUSION: Results of the transanal pull-through have improved likely as a result of a combination of experience and use of a shorter rectal muscular cuff. The use of a preliminary colonic biopsy through an umbilical incision has not increased @entity282 , prolonged operative time, or lengthened hospital stay.

title: Evolution of the technique in the transanal pull-through for XXXX : effect on outcome.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients']

entities_list: @entity1964 :: ('MESH:D004760', 'Disease') :: ['enterocolitis']

entities_list: @entity282 :: ('MESH:D010149', 'Disease') :: ['postoperative pain']

entities_list: @entity1963 :: ('MESH:D006627', 'Disease') :: ["Hirschsprung's disease"]

answer: @entity1963 :: (MESH:D006627,Disease) :: ['Hirschsprung's disease']


abstract: The larynx is the most common site of @entity5 in the upper aerodigestive tract. In Brazil, @entity5 represent 2% of all @entity5 , with approximately 3000 annual deaths. The association between @entity1082 ) and @entity5 is still controversial. The aim of the present retrospective study was to determine the expression of galectin-3 immunoperoxidase in @entity189 by examining paraffin-embedded larynx biopsies from 65 @entity1 , 10 in situ @entity189 , 27 @entity189 without @entity3 , and 28 with @entity3 . Twenty-eight cervical lymph nodes from @entity1 with metastatic lesions were also evaluated. Nested PCR was performed to detect and type HPV DNA. Galectin-3 expression was assessed by immunohistochemistry using a computer-assisted system. Among 65 @entity1 , 55 (84.6%) were positive to beta-globin (internal control); 10 (15.4%) @entity1 were beta-globin negative and were excluded from the HPV evaluation. Thus, 7 (12.7%) out of 55 @entity1 were HPV positive and 48 (87.3%) out of 55 @entity1 were HPV negative. High expression of galectin-3 was observed in invasive @entity5 , suggesting that galectin-3 could be associated with the invasiveness and @entity146 .

title: Galectin-3 overexpression in invasive XXXX , assessed by computer-assisted analysis.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['aggressiveness of laryngeal carcinomas']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['malignant laryngeal lesions', 'laryngeal cancer', 'cancers', 'laryngeal tumors', 'malignancy']

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['laryngeal carcinomas', 'laryngeal carcinoma']

entities_list: @entity1082 :: ('10566', 'Species') :: ['human papillomavirus (HPV']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases']

answer: @entity189 :: (MESH:D002277,Disease) :: ['laryngeal carcinoma']


abstract: The aim of the study was to achieve earlier diagnosis of @entity1745 ( @entity1745 ) using urgent magnetic resonance imaging (MRI) for selected @entity1 . A comparison was carried out of the current prospective audit of 100 @entity1 referred by a general practitioner or a consultant over 32 months with both a previous national @entity28482 ( @entity28482 ) prospective audit (324 cases of @entity1745 ) and an earlier retrospective audit of 104 @entity1 referred with suspected @entity1745 . A telephone hotline rapid-referral process for @entity1 with known @entity5 and new symptoms (severe nerve @entity158 +/- severe back @entity158 ) was designed. @entity1 were considered for urgent MRI after discussion with a senior clinician responsible for the hotline. Appropriate referrals were discussed with radiology and oncology ensuring timely MRI reporting and intervention. The main outcome measures are as follows: time from referral to diagnosis; time from the onset of symptoms to diagnosis; and mobility at diagnosis. A total of 50 @entity1 (52%) of those scanned had either @entity1745 (44) or @entity614 (6) compared with the earlier rate of 23 out of 104 @entity1 (22%). Ten out of 44 @entity1745 @entity1 (23%) were @entity912 at diagnosis, compared with 149 out of 324 (46%) in the @entity28482 audit. Time from reporting @entity158 to diagnosis was 32 days compared with 89 days in the @entity28482 audit. Median time from referral to diagnosis was 1 day, again considerably shorter than the @entity28482 audit time of 15 days (interquartile (IQ) range: 3-66). In @entity1 at risk of @entity1745 , fast-track referral with rapid access to MRI reduces time between symptom onset and diagnosis, improves mobility at diagnosis and reduces the number of negative MRI scans.

title: Suspected XXXX - improving time to diagnosis via a 'hotline': a prospective audit.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['malignancy']

entities_list: @entity28482 :: ('116988', 'Gene') :: ['Clinical Research and Audit Group', 'CRAG']

entities_list: @entity1745 :: ('MESH:D013117', 'Disease') :: ['MCC', 'malignant cord compression']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['root pain', 'pain']

entities_list: @entity614 :: ('MESH:D011843', 'Disease') :: ['malignant nerve root compression']

entities_list: @entity912 :: ('MESH:D010243', 'Disease') :: ['paralysed']

answer: @entity1745 :: (MESH:D013117,Disease) :: ['malignant cord compression']


abstract: BACKGROUND: Arterial @entity101 affects endothelial function and arterial @entity2693 . The angiotensin (AT1) receptor antagonist @entity7056 improves endothelial function and arterial @entity2693 in @entity101 @entity1 . @entity23191 , a beta(1)-selective beta blocker, reduces systemic vascular resistance and stimulates @entity842 release thus exerting positive effects on vascular function. However, comparative studies on the vascular effects of third generation beta-blockers and AT1 receptor blockers are lacking. Aim of this randomized, double-blind study was to test the hypothesis of non-inferiority of @entity23191 to @entity7056 , both in association with @entity918 , on endothelial function, arterial @entity2693 and central hemodynamic parameters in @entity1 with arterial @entity101 na  ve on therapy. METHODS: Sixty-five @entity1 were randomized to receive @entity7056 / @entity918 (150 mg/12.5 mg day) or @entity23191 / @entity918 (5mg/12.5 mg day) for 8-weeks. Endothelial function, pulse wave velocity, augmentation index, central and brachial blood pressures were measured at baseline and at the end of the study. RESULTS: Systolic and diastolic central blood pressure, as well as brachial arterial pressure, decreased to a similar extent after both treatments. Similar changes in endothelial function between groups were detected at the end of the study. A significant reduction in pulse wave velocity, central blood pressure, and augmentation index adjusted for heart rate, was found in both the treatment groups at the end of the study, without significant differences between groups. CONCLUSIONS: The results of this study confirm the hypothesis of non-inferiority of short-term treatment with @entity23191 compared to @entity7056 , both in association with @entity918 , on endothelial function, arterial @entity2693 and central hemodynamic parameters in @entity101 @entity1 na  ve on therapy.

title: Effects of XXXX or @entity7056 in combination with @entity918 on vascular functions in newly-diagnosed @entity101 @entity1 : the NINFE (Nebivololo, @entity7056 Nella Funzione Endoteliale) study.

entities_list: @entity23191 :: ('MESH:C052753', 'Chemical') :: ['Nebivolol', 'nebivolol']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension', 'hypertensive']

entities_list: @entity918 :: ('MESH:D006852', 'Chemical') :: ['hydrochlorothiazide']

entities_list: @entity7056 :: ('MESH:C081309', 'Chemical') :: ['irbesartan']

entities_list: @entity842 :: ('MESH:D009569', 'Chemical') :: ['nitric oxide']

entities_list: @entity2693 :: ('MESH:C566112', 'Disease') :: ['stiffness']

answer: @entity23191 :: (MESH:C052753,Chemical) :: ['nebivolol']


abstract: BACKGROUND: @entity263 is now often diagnosed in the localized, welldifferentiated stage. In the HAROW study, we investigated the care situation with respect to the various treatment options for @entity263 in everyday clinical practice in Germany. METHODS: Study physicians for this prospective, multicenter observational study were recruited through the Federation of German Urologists. At six-month intervals, clinical variables were recorded (T category, @entity1486 [PSA], Gleason score, d'Amico risk profile, Charlson Comorbidity Index [CCI]) and @entity1 filled out questionnaires (QLQ-C30) regarding their indicationrelated quality of life (QoL). Covariance analysis was used to adjust for the variable distribution of @entity1 features among the treatment groups. RESULTS: Data from 2957 @entity1 were available for analysis. The mean followup time was 28.4 months overall, and 47.6 months in the @entity3457 ( @entity3457 ) group. Younger @entity1 and @entity1 with a CCI of 0 or 1 predominated in the @entity3457 and surgery groups; older @entity1 and @entity1 with a CCI of 2 or above predominated in the groups in which palliative treatment strategies such as hormone therapy (HT) and watchful waiting were applied. The HT group had the highest percentage of @entity1 with a Gleason score of 8 or above (21.2%), while the @entity3457 group had the highest percentage of @entity1 with a Gleason score of 6 or below (92.5%), as well as the lowest mean PSA value (5.8    3.4 ng/mL) and the highest percentage of @entity1 with a low-risk profile (82.5%). Of 468 @entity1 in the @entity3457 group, 170 (36.3%) underwent a change of treatment strategy. After adjustment for the severity of disease, no significant difference with respect to the global quality of life was found between @entity3457 and the curative treatment options over the long term. CONCLUSION: The study physicians drew a clear distinction between curative and palliative treatment strategies, and the inclusion criteria for @entity3457 were largely respected. The observed preference for surgery in low-risk @entity1 indicates overtreatment in this @entity1 group.

title: The Treatment of Localized XXXX in Everyday Practice in Germany.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity263 :: ('MESH:D011471', 'Disease') :: ['localized prostate cancer', 'Prostate cancer']

entities_list: @entity3457 :: ('OMIM:612348', 'Disease') :: ['active surveillance', 'AS']

entities_list: @entity1486 :: ('354', 'Gene') :: ['prostate-specific antigen']

answer: @entity263 :: (MESH:D011471,Disease) :: ['Prostate Cancer']


abstract: The authors evaluate the accuracy and practical applications of flow cytometry (FCM) on bladder lavage fluid in the diagnosis and follow-up of @entity150 . The apparatus used was a Coultronics Epics Profile II cytofluorograph. Two hundred and fifteen samples were obtained with a yield of 86%. The specimens were preserved in @entity1068 . The staining was performed on whole cells with preservation of the cytoplasm. The analysis of a control group of 45 @entity1 confirmed that the FCM study of ploidy was specific (0.97 for normal bladders and 0.8 for inflammatory lesions). Four aspects were evaluated: Correlation between FCM and the histological type of the @entity5 : a significant difference was observed between the control group, the invasive @entity5 group (p < 0.01) and the @entity189 in situ group (< 0.001). A significant difference was observed in the case of high-grade PTA and @entity2558 @entity5 . No significant difference was observed between FCM and classical cytodiagnosis when this technique was performed by a trained cytologist. Predictive value of FCM for the recurrence of PTA and @entity2558 @entity5 : 40 @entity1 were followed with a mean follow-up of 13 months. The relative risk of recurrence in the case of a @entity5 with an abnormal FCM was 2 (p < 0.05). FCM and monitoring of conservatively treated @entity5 : 30 @entity1 with normal endoscopic examination after endoscopic resection of a PTA or @entity2558 @entity5 underwent cytometric analysis and cytodiagnosis. In the case of an abnormality on cytometry, randomised bladder biopsies and urography were performed. The positive predictive value for the presence of a lesion not diagnosed by cystoscopy and detected by FCM was 0.38 +/- 0.26. FCM and intravesical chemotherapy: 16 @entity1 with @entity2558 @entity5 and abnormal FCM received BCG therapy (11 @entity1 ) or @entity1138 instillations (5 @entity1 ). A significant difference (p < 0.01) was observed between the 2 treatments in terms of normalisation of cytometry.(ABSTRACT TRUNCATED AT 400 WORDS)

title: [Flow cytometry in bladder lavage fluid for the diagnosis and surveillance of XXXX . Preliminary results].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumours', 'tumour']

entities_list: @entity1138 :: ('MESH:D016685', 'Chemical') :: ['mitomycin C']

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinoma']

entities_list: @entity150 :: ('MESH:D001749', 'Disease') :: ['bladder tumours']

answer: @entity150 :: (MESH:D001749,Disease) :: ['bladder tumors']


abstract: @entity1534 (H.p.), has been shown, experimentally, to exert a proteolytic activity against mucous fractions. Aim of this study was to assess the prevalence of H.p. in peptic @entity1066 and to analyze its possible influence on gastric mucus components, on peptic activity in gastric juice and the possible action on peptic secretion. 223 @entity1 undergoing upper gastrointestinal endoscopy were analyzed for the presence of H.p. in the mucosa: 99 duodenal @entity1066 @entity1 (D.U.), 58 gastric @entity1066 @entity1 (D.U.) and 66 dyspeptic subjects. In each @entity1 , three contiguous gastric biopsies were taken at the antrum: the first was evaluated for @entity3621 (Whitehead Criteria), the two other analyzed for H.p. with a rapid urease test. In a subgroup of 25 D.U. and 18 G.U. @entity1 , two other biopsies were taken at the fundus corpus of the stomach, to evaluate peptic secretion. To determinate mucous components (acid and neutral @entity32291 , @entity3649 and @entity3167 ), gastric juice samples were collected during endoscopy. H.p. was present in 89% of antral biopsies in D.U., in 56% of G.U. and in 51% of D., and was associated to antral @entity3621 . As regard gastric juice components, we observed an increase and a decrease of acid glycoproteins, respectively, in D.U. and G.U. @entity1 with H.p. @entity281 . An increase of peptic activity has been found in the gastric juice of both gastric and duodenal @entity1066 @entity1 H.p. positive (G.U. p less than 0.05). On the contrary, no significant differences were observed on peptic activity in the fundus-corpus biopsies between H.p. positive and H.p. negative @entity1 .(ABSTRACT TRUNCATED AT 250 WORDS)

title: [Does @entity1534 have a direct proteolytic effect in XXXX ?].

entities_list: @entity3167 :: ('MESH:D019158', 'Chemical') :: ['N-acetylneuraminic acid']

entities_list: @entity32291 :: ('CHEBI:17089', 'Chemical') :: ['glycoproteins']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']

entities_list: @entity3649 :: ('MESH:D005690', 'Chemical') :: ['galactose']

entities_list: @entity3621 :: ('MESH:D005756', 'Disease') :: ['gastritis']

entities_list: @entity1534 :: ('210', 'Species') :: ['Helicobacter pylori']

answer: @entity1066 :: (MESH:D014456,Disease) :: ['ulcerative disease']


abstract: OBJECTIVE: The objective of this systematic review was to assess the effectiveness of yoga as a complementary treatment on general psychopathology, positive and negative symptoms and health-related quality of life (HRQL) for @entity1 with @entity161 . METHOD: Randomised controlled trials (RCTs) were considered whether they investigated a yoga intervention in @entity1 with @entity161 . The selection of studies, data extraction and quality assessment were performed independently by two reviewers. RESULTS: Only three RCTs met the inclusion criteria. Lower Positive and Negative Syndrome Scale (PANSS) total scores and subscale scores for positive and negative symptoms were obtained after yoga compared with exercise or waiting list control conditions. In the same way, the physical, @entity6100 as measured with the abbreviated version of the World Health Organization Quality of Life questionnaire (WHOQOL-BREF) increased more significantly after yoga than after exercise or waiting list control conditions. None of the RCTS encountered adverse events. Dose-response relationships could, however, not be determined. CONCLUSION: Although the number of RCTs included in this review was limited, results indicated that yoga therapy can be an useful add-on treatment to reduce general psychopathology and positive and negative symptoms. In the same way, HRQL improved in those antipsychotic-stabilised @entity1 with @entity161 following yoga.

title: Yoga in XXXX : a systematic review of randomised controlled trials.

entities_list: @entity1 :: ('9606', 'Species') :: ['people', 'patients']

entities_list: @entity6100 :: ('OMIM:300082', 'Disease') :: ['psychological, social and environmental HRQL']

entities_list: @entity161 :: ('MESH:D012559', 'Disease') :: ['schizophrenia']

answer: @entity161 :: (MESH:D012559,Disease) :: ['schizophrenia']


abstract: BACKGROUND: @entity158 is a common adverse effect of dermatological laser procedures. Currently, no standard topical anaesthetic cream exists for deeper dermal laser procedures. OBJECTIVES: To compare the efficacy of @entity3303 / @entity6513 cream and @entity3303 / @entity5403 cream in reducing self-reported @entity158 during deeper dermal laser treatment of @entity36175 ( @entity36175 ) and tattoos. METHODS: We conducted two randomized, double-blind, controlled clinical trials with intrapatient, split-lesion designs: study A included @entity1 with @entity36175 (n = 15); study B included @entity1 with black tattoos (n = 15). The primary end point was the @entity1 ' self-reported @entity158 on a 10-cm visual analogue scale (VAS). Secondary objectives were the percentage of @entity1 with adequate @entity158 relief, willingness to pay    25 for the cream that provided the @entity158 relief and safety of the creams. RESULTS: In both studies, VAS scores were lower for @entity3303 / @entity5403 cream, with a mean VAS difference in study A of 1  9 [95% confidence interval (CI) 1  0-2  8] and in study B of 0  6 (95% CI -0  7 to 1  9). In study A, adequate @entity158 relief was achieved in 13% (n = 2) with @entity3303 / @entity6513 cream vs. 73% (n = 11) with @entity3303 / @entity5403 cream (P = 0  004), and in study B in 53% (n = 8) vs. 80% (n = 12), respectively (P = 0  289). In study A, 47% (n = 7) were willing to pay an additional    25 vs. 73% (n = 11) in study B. No serious adverse events occurred. CONCLUSIONS: @entity3303 / @entity5403 cream under plastic occlusion is the preferred topical anaesthetic during painful laser procedures targeting dermal chromophores.

title: Comparison of @entity3303 / XXXX cream and @entity3303 / @entity5403 cream for local anaesthesia during laser treatment of @entity36175 and tattoo removal: results of two randomized controlled trials.

entities_list: @entity5403 :: ('MESH:D011318', 'Chemical') :: ['prilocaine']

entities_list: @entity36175 :: ('MESH:D000153', 'Disease') :: ['AKN', 'acne keloidalis nuchae']

entities_list: @entity6513 :: ('MESH:D013748', 'Chemical') :: ['tetracaine']

entities_list: @entity3303 :: ('MESH:D008012', 'Chemical') :: ['Lidocaine', 'lidocaine']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['Pain', 'pain', 'best pain']

answer: @entity6513 :: (MESH:D013748,Chemical) :: ['tetracaine']


abstract: INTRODUCTION: @entity9718 ( @entity427 , @entity508 , Babinski sign) are essential for the diagnosis of @entity746 ( @entity746 ). However, these signs are not always present at onset and may vary over time, besides which their role in disease evolution is controversial. Our goal was to describe which pyramidal signs were present and how they evolved in a cohort of @entity1 with @entity746 , as well as their role in prognosis. METHODS: Retrospective analysis of prospectively collected @entity1 diagnosed with @entity746 in our centre from 1990 to 2015. RESULTS: Of a total of 130 @entity1 with @entity746 , 34 (26.1%) @entity1 showed no pyramidal signs at the first visit while 15 (11.5%) had a @entity9917 . Of those @entity1 without initial pyramidal signs, mean time of appearance of the first signs was 4.5 months. Babinski sign was positive in 64 (49.2%) @entity1 , @entity427 in 90 (69.2%) and 22 (16.9%) @entity1 had @entity508 . @entity9718 tended to remain unchanged over time, although they seem to appear at later stages or even disappear with time in some @entity1 . We found no association between survival and the presence of changes to pyramidal signs, although decreased @entity508 was associated with greater clinical deterioration (ALSFR scale) (P<.001). CONCLUSION: A quarter of @entity1 with @entity746 initially showed no pyramidal signs and in some cases they even disappear over time. These data support the need for tools that assess the pyramidal tract.

title: Relevance of the @entity9917 in XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity9917 :: ('MESH:C538104', 'Disease') :: ['complete pyramidal syndrome']

entities_list: @entity9718 :: ('MESH:D015419', 'Disease') :: ['Pyramidal signs']

entities_list: @entity508 :: ('MESH:D009128', 'Disease') :: ['spasticity']

entities_list: @entity746 :: ('MESH:D000690', 'Disease') :: ['ALS', 'amyotrophic lateral sclerosis']

entities_list: @entity427 :: ('MESH:D012021', 'Disease') :: ['hyperreflexia']

answer: @entity746 :: (MESH:D000690,Disease) :: ['amyotrophic lateral sclerosis']


abstract: OBJECTIVE: Adverse microbial exposures might contribute to diabetogenesis. We hypothesized that @entity2520 (a manifestation of microbial exposures in dysbiotic biofilms) would be related to @entity2690 resistance among @entity6 -free @entity1 . The roles of inflammatory mediation and effect modification were also studied. RESEARCH DESIGN AND METHODS: The continuous National Health and Nutrition Examination Survey 1999-2004 enrolled 3,616 @entity1 (51% @entity1 ) who received a periodontal examination and fasting blood draw. @entity1 were mean age (   SD) 43    17 years and 28% Hispanic, 52% Caucasian, 17% African American, and 3% other. Log-transformed values of the homeostasis model assessment of @entity2690 resistance (HOMA-IR) or HOMA-IR >= 3.30 (75th percentile) were regressed across full-mouth periodontal @entity92 ( @entity92 ) levels using linear and logistic models. White blood cell (WBC) count and @entity1851 ( @entity1851 ) were considered as either mediators or effect modifiers in separate analyses. Risk ratios (RRs) stem from marginal predictions derived from the logistic model. Results were adjusted for @entity2520 and @entity2690 resistance risk factors. RESULTS: In linear regression, geometric mean HOMA-IR levels increased by 1.04 for every 1-mm @entity92 increase (P = 0.007). WBC mediated 6% of the association (P < 0.05). Among @entity1 with WBC  <=6.4   10(9), @entity92 was unrelated to HOMA-IR >= 3.30. Fourth-quartile @entity92 was associated with HOMA-IR >= 3.30 among @entity1 with WBC >7.9   10(9); RR 2.60 (1.36-4.97) (P for interaction = 0.05). Findings were similar among @entity1 with @entity1851 >3.0 mg/L (P for interaction = 0.04). CONCLUSIONS: Periodontal @entity281 was associated with @entity2690 resistance in a nationally representative U.S. sample of @entity6 . These data support the role of @entity32 as both mediator and effect modifier of the association.

title: @entity32 , and XXXX resistance: results from the continuous National Health and Nutrition Examination Survey (NHANES) 1999-2004.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'women', 'Participants']

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes', 'diabetes-free adults']

entities_list: @entity2520 :: ('MESH:D010510', 'Disease') :: ['clinical periodontal disease', 'multiple periodontal disease']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']

entities_list: @entity92 :: ('MESH:D007222', 'Disease') :: ['PD', 'probing depth']

entities_list: @entity1851 :: ('1401', 'Gene') :: ['C-reactive protein', 'CRP']

answer: @entity2690 :: (3630,Gene) :: ['insulin']


abstract: Vaccines inducing pathogen-specific cell-mediated immunity are being developed using attenuated adenoviral (Ad) vectors. We report the results of two independent Phase I trials of similar replication-deficient @entity11650 vaccines containing a near-consensus @entity2858 clade B @entity5024 transgene. Healthy @entity645 -uninfected adults were enrolled in two separate, multicenter, dose-escalating, blinded, placebo-controlled studies to assess the safety and immunogenicity of a three-dose homologous regimen of @entity11650 and MRKAd5 @entity2858 @entity5024 vaccines given on day 1, week 4, and week 26. Adverse events were collected for 29 days following each intradeltoid injection. The primary immunogenicity endpoint was the proportion of subjects with a positive unfractionated @entity5024 -specific IFN-gamma ELISPOT response measured 4 weeks after the last dose (week 30). Analyses were performed after combining data for each dose group from both protocols, stratifying by baseline @entity11650 titers. Overall, 252 subjects were randomized to receive either vaccine or placebo, including 229 subjects (91%) who completed the study through week 30. Tolerability and immunogenicity did not appear to differ between the @entity11650 and MRKAd5 vaccines. The frequency of injection-site reactions was dose dependent. Systemic adverse events were also dose dependent and more frequent in subjects with baseline @entity11650 titers <200 versus > or =200, especially after the first dose. The percent of ELISPOT responders and the ELISPOT geometric means overall were significantly higher for all four vaccine doses studied compared to placebo, and were generally higher in vaccine recipients with baseline @entity11650 titers <200 versus > or = 200. @entity11650 titers increased after vaccination in a dose-dependent fashion. Both @entity11650 -vectored @entity2858 vaccines were generally well tolerated and induced cell-mediated immune responses against @entity645 @entity5024 -peptides in the majority of healthy adults with baseline @entity11650 titers <200. Preexistent and/or vaccine-induced immunity to the @entity11650 vector may dampen the CMI response to @entity645 @entity5024 .

title: Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B XXXX vaccines in healthy adults.

answer: @entity5024 :: (155030(Tax:11676),Gene) :: ['gag']


abstract: On the basis of a review of the literature and five case histories, the pathophysiological and clinical features in pregnant @entity1 with haemolysis, elevated liver enzymes and @entity882 which together constitute the @entity2102 (haemolysis, elevated liver enzymes and low platelet count) are illustrated. This syndrome describes a complicated obstetric course with greatly increased neonatal and maternal morbidities. @entity101 / @entity644 are common but are not obligatory. The condition should be suspected in pregnant @entity1 with @entity158 under the right rib margin and unexplained @entity1087 . The diagnosis is verified by the blood picture, liver enzyme count and a blood smear. @entity1 with verified @entity2102 and gestational age greater than 34 weeks should be delivered immediately. @entity1 with the same syndrome and gestational age less than 32 weeks should be delivered if the condition cannot be rapidly controlled. In exceptional cases cesarean section may be necessary. On the basis of the coagulation status, the defective plasma components may be supplied (e.g. fresh frozen plasma and antithrombin-III). Plasmapheresis and specific pharmacological intervention must be considered as experimental at present, although these present promising therapeutic possibilities.

title: [Hemolysis, elevated liver enzymes and @entity882 : the XXXX --a manifestation of severe pre-eclampsia].

entities_list: @entity644 :: ('MESH:D011507', 'Disease') :: ['proteinuria']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['Hypertension']

entities_list: @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia']

entities_list: @entity2102 :: ('MESH:D017359', 'Disease') :: ['HELLP syndrome']

answer: @entity2102 :: (MESH:D017359,Disease) :: ['HELLP syndrome']


abstract: UNASSIGNED: @entity3884 / @entity6189 exchange coupled with mass spectrometry (HDX- @entity15 ) is an information rich biophysical method for the characterization of protein dynamics. Successful applications of differential HDX- @entity15 include the characterization of protein-ligand binding. A single differential HDX- @entity15 dataset (protein +/- ligand) is often comprised of more than forty individual HDX- @entity15 experiments. In order to eliminate laborious manual processing of samples, and to minimize random and gross errors, automated systems for HDX- @entity15 analysis have become routine in many laboratories. However, an automated system, while less prone to random errors introduced by @entity1 operators, may have systematic errors that go unnoticed without proper detection. Although the application of automated (and manual) HDX- @entity15 has become common, there are only a handful of studies reporting the systematic evaluation of the performance of HDX- @entity15 experiments and no reports have been published describing a cross-site comparison of HDX- @entity15 experiments. Here we describe an automated HDX- @entity15 platform that operates with a parallel, two-trap, two-column configuration that has been installed in two remote laboratories. In order to understand the performance of the system both within and between laboratories, we have designed and completed a test-retest repeatability study for differential HDX- @entity15 experiments implemented at each of two laboratories, one in Florida and the other in Spain. This study provided sufficient data to do both within- and between-laboratory variability assessments. Initial results revealed a systematic run order effect within one of the two systems. Therefore, the study was repeated and this time the conclusion was that the experimental conditions were successfully replicated with minimal systematic error.

title: A Two-Site Evaluation of the Repeatability and Precision of an Automated Dual-Column XXXX / @entity6189 Exchange Mass Spectrometry Platform.

entities_list: @entity3884 :: ('MESH:D006859', 'Chemical') :: ['Hydrogen']

entities_list: @entity6189 :: ('MESH:D003903', 'Chemical') :: ['deuterium']

answer: @entity3884 :: (MESH:D006859,Chemical) :: ['Hydrogen']


abstract: OBJECTIVE: @entity7 ( @entity7 ) and its receptors @entity7 -R1, -R2 and -R3 play important roles in @entity5 angiogenesis and are associated with poor prognosis in several solid @entity5 . However, their functional significance remains unclarified. Here, we investigated the associations between the expression of these receptors and the clinical outcomes of @entity14 ( @entity14 ) @entity1 . METHODS: An immunohistochemical approach was used to detect @entity7 -R1, -R2 and -R3 expression in 91 @entity14 @entity1 who underwent surgery and received chemotherapy at the National @entity5 Center Hospital. Statistical analysis was performed to determine the prognostic significance of these biomarkers. RESULTS: Immunoreactivity for @entity33246 was localized in microvessels and that for @entity6758 in @entity5 cells and stromal microvessels. @entity6758 staining in @entity5 cells (>10% staining) was found in 84 @entity1 (92%) and in stromal vessels in 75 @entity1 (82%). @entity319 staining in @entity5 vessels (>10% staining) was found in 84 @entity1 (92%), whereas @entity7802 staining was found in 85 @entity1 (93%). Strong positive staining (>60% staining) of @entity6758 in @entity5 cells, and @entity7 -R1, -R2 and -R3 in vessels was identified in 58 (64%), 33 (36%), 52 (57%) and 60 (66%) @entity1 , respectively. Univariate analysis revealed that @entity6758 strong positive staining correlated with shorter post-operative survival in @entity1 with @entity5 (P = 0.01), but neither @entity319 nor R3 expression correlated with survival. CONCLUSIONS: @entity7 -R1, -R2 and -R3 were highly expressed in @entity14 cells and stromal vessels. @entity6758 strong positive staining correlated with shorter survival after @entity14 surgery.

title: @entity7 receptor expression as a prognostic marker for survival in XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity7 :: ('7422', 'Gene') :: ['VEGF', 'Vascular endothelial growth factor']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer', 'Stage II/III disease', 'tumors', 'Cancer']

entities_list: @entity14 :: ('MESH:D015179', 'Disease') :: ['CRC', 'colorectal cancer']

answer: @entity14 :: (MESH:D015179,Disease) :: ['colorectal cancer']